Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.27 (
thermolysin
)
1,894
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
p53
is a sequence-specific DNA-binding oligomeric protein that can activate transcription from promoters bearing
p53
-binding sites. Whereas the activation region of
p53
has been identified within the amino terminus, the location of the specific DNA-binding domain has not been reported. Thermolysin treatment of
p53 protein
generates a stable protease-resistant fragment that binds with marked specificity to
p53
DNA-binding sites. Amino-terminal sequencing of the fragment located the
thermolysin
cleavage site to residue 91. Because the fragment does not contain the cdc2 phosphorylation site at Ser-315, we conclude that the the site-specific DNA-binding domain of
p53
spans the central region of the protein. The vast majority of the mutations in oncogenically derived
p53
proteins are located within this central portion of the molecule. Such mutant p53 proteins exhibit defective sequence-specific DNA-binding. Although
thermolysin
digestion of mutant p53 proteins generates proteolytic patterns that differ from wild-type protein, one mutant tested, His-273, generates a resistant fragment that migrates with a similar electrophoretic mobility to the wild-type protease-resistant fragment. Interestingly, although intact mutant His-273 protein binds to DNA at 20 degrees C, the
thermolysin
-resistant mutant fragment does not. In addition, the central protease-resistant, site-specific binding region of wild-type
p53
does not demonstrate nonspecific DNA-binding. Thus, although sequences outside of the central region of
p53
contribute to both nonspecific DNA-binding and oligomerization, they are not required for sequence-specific DNA-binding.
...
PMID:A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein. 827 39